Background: Subcortical band heterotopia (SBH, or double cortex syndrome) is a neuronal migration disorder consisting of heterotopic bands of gray matter located between the cortex and the ventricular surface, with or without concomitant pachygyria. Most cases show diffuse or anteriorly predominant (AϾP) migration abnormality. All familial and 53% to 84% of sporadic cases with diffuse or AϾP SBH harbor a mutation of the DCX gene, leaving the genetic causes unexplained, and genetic counseling problematic, in the remaining patients. Our purpose was to verify the extent to which exonic deletions or duplications of the DCX gene would account for sporadic SBH with AϾP gradient but normal gene sequencing. Methods: We identified 23 patients (22 women, 1 man) with sporadic, diffuse, or anteriorly predominant SBH. After sequencing the DCX gene and finding mutations in 12 (11 women, 1 man), we used multiplex ligation-dependent probe amplification (MLPA) to search for whole-exon deletions or duplications in the 11 remaining women. We used semiquantitative fluorescent multiplex PCR (SQF-PCR) and Southern blot to confirm MLPA findings. Results: MLPA assay uncovered two deletions encompassing exons 3 to 5, and one involving exon 6, in 3 of 11 women (27%) and raised the percentage of DCX mutations from 52% to 65% in our series. SQF-PCR performed in all three women and Southern blot analysis performed in two confirmed the deletions. Conclusions: MLPA uncovers large genomic deletions of the DCX gene in a subset of patients with SBH in whom no mutations are found after gene sequencing. Deletions of DCX are an underascertained cause of SBH.
Subcortical band heterotopia (SBH, or double cortex syndrome) is a neuronal migration disorder consisting of ribbons of gray matter located within the central white matter between the cortex and the ventricular surface. The gyral pattern is usually simplified with broad convolutions, and cortical thickness is often increased. 1 SBH comprises part of a spectrum of phenotypes that are associated with lissencephaly and that are caused by alterations in at least two genes: LIS1 (also known as PAFAH1B1) at 17p13.3 2 , and doublecortin (DCX) at Xq22.3-q23. 3, 4 Mutations of the DCX gene cause SBH in heterozygous females 5, 6 and X-linked isolated lissencephaly sequence (XLIS) in hemizygous males, 7 although rare males with SBH and DCX mutations have been reported. 8, 9 Patients with DCX mutations show more severe migration abnormality over the anterior brain regions, defining an anterior greater than posterior gradient (AϾP) that differs from the PϾA gradient observed in LIS1 alterations. 7, 10, 11 Mutations of the DCX gene have been found in all familial cases and in 53% 12 to 84% 13 of patients with sporadic, diffuse, or anteriorly predominant band heterotopia, which represent the most common forms of SBH. 12, 13 The genetic cause for the remaining sporadic patients not harboring DCX mutations remains unexplained. However, besides the possible implication of other gene(s) or of mutations in noncoding regions of DCX, large deletions or duplications (encompassing one or more exons) and cryptic chromosomal abnormalities involving DCX might still be involved.
Most DCX mutations are single-base substitutions and small insertions or deletions, leading to missense, nonsense, or splice-site mutations. 6, 8, 12, 13 Large deletions of DCX have, until now, been detected through PCR in two boys with XLIS and were subsequently confirmed in female relatives in one case. 13, 14 In women with SBH, these deletions are not identifiable using standard mutation analysis (single-strand conformation polymorphism [SSCP], denaturing gradient gel electrophoresis [DGGE], or DNA sequencing).
To evaluate the frequency of whole-exon deletions or duplications, we used multiplex ligationdependent probe amplification (MLPA) to study 11 women with sporadic SBH who had no DCX mutations on DNA sequencing. MLPA has proven sensitive and reliable for identifying large deletions/ duplications in genes associated with other diseases. 15 Methods. In our cohort of patients showing phenotypes consisting with the agyria-pachygyria-SBH spectrum, we identified 23 patients (22 women and 1 man) with sporadic, diffuse, or anteriorly predominant SBH. This pattern of malformation is highly indicative of X-linked SBH. For this reason, we performed in all patients mutation analysis of the DCX gene using the methods illustrated below (see Mutation analysis section) and found mutations in 52% (12 of 23) of patients.
Clinical information, brain MRI, and blood or DNA samples were obtained after informed consent was given. In addition to the 23 patients, we also included in the analysis a boy with XLIS and a known DCX deletion and his mother, to validate the MLPA assay.
MLPA identified gene deletions in three women. To validate MLPA findings, we also performed single multiplex semiquantitative fluorescent PCR analysis (SQF-PCR) in all three women and Southern blot analysis in two for whom DNA was still available (Patients 2 and 3).
Mutation analysis. Genomic DNA was extracted from peripheral blood leukocytes using a DNA isolation kit according to the manufacturer's protocol (DNAzol, MRC, Cincinnati, OH). The six exons covering the coding regions of DCX (Entrez Gene, GeneID: 1641) and their respective intron-exon boundaries were amplified by PCR. Exons 3, 4, and 5 were each divided into two overlapping PCR products. Primer sequences and PCR conditions are available on request. PCR amplicons were purified using the GenElute PCR clean-up kit (Sigma Aldrich, St. Louis, MO) and were cycle sequenced on both strands using the BigDye Terminator v.1.1 chemistry (Applied Biosystems, Foster City, CA). The products were analyzed on an ABI Prism 3100 Avant DNA sequencer (Applied Biosystems, Foster City CA).
MLPA analysis. MLPA was performed using the Lissencephaly probe kit (SALSA P61 Lissencephaly, MRC Holland, Amsterdam, Holland) including seven paired probes for the DCX coding exons and 33 paired probes specific for other genes and chromosomal regions. All DCX paired probe ligation sites were located in the coding regions of the gene. Single-nucleotide substitutions or small deletions/insertions at such ligation sites or near enough to affect the probe hybridization could decrease the peak signals, generating false-positive results. To exclude this scenario, all DCX ligation sites have been carefully examined by DNA sequencing, as described in the Mutation analysis section.
Genomic DNA (100 ng) diluted in 5 L of Tris-EDTA 10 mM was denatured at 95°C for 5 minutes, mixed with the probe set and the MLPA buffer, and incubated for 16 hours at 60°C. After probe hybridization, products were ligated for 15 minutes at 54°C. Ligase enzyme was then inactivated with an incubation of 5 minutes at 98°C. The ligation products were subsequently amplified by PCR, using a 6-FAM labeled forward primer. The resulting products were separated on an ABI 3100 Avant sequencer (Applied Biosystems, Foster City CA) and sized using ROX-500 (Applied Biosystems, Foster City CA) as internal standard. Peaks corresponding to DCX exons were identified according to their size. Electropherograms were evaluated by visual examination of peak heights of the DCX fragments in relation to the adjacent fragments and in comparison with external female or male control DNA according to each patient's gender. In addition, peak areas were exported to a Microsoft Excel spreadsheet and subsequently normalized as previously reported. 16 Normalization of data are required because variations in experimental conditions may con-tribute to quantitative differences of measured values between samples. Values of 1.5 to 2.5 in females (0.75 to 1.25 in males) indicate normal results, whereas values Ͻ1.5 or Ͼ2.5 (Ͻ0.75 or Ͼ1.25 in males) indicate a deletion or a duplication. Using this method, we identified three deletions that were confirmed with a second MLPA reaction.
SQF-PCR. Primers and PCR conditions are available online (table E-1 on the Neurology Web site at www.neurology.org). The multiplex SQF-PCR contained amplimers for exons 3, 4, 5, and 6 of DCX, with exon 25 of SCN1A and exon 8 of LGI1 used as controls (table E-1). Forward primers were labeled with the 6-FAM fluorophore. Fluorescent PCR products were run on an ABI 3100 Avant Sequencer (Applied Biosystems, Foster City CA), and the resulting data were exported using Genemapper software (Applied Biosystems, Foster City CA). Data were analyzed as described by Flintoff et al. 17 A dosage quotient close to 1.0 indicated that two copies of the exon were present, whereas a value close to 0.5 indicated the presence of only one copy of the exon.
Southern blot analysis. Exons 4, 6, and 7 of the DCX gene were amplified in a PCR reaction using standard dNTPs, 32 P dCTPs, and specific oligonucleotides to generate three radiolabeled probes. Oligonucleotide sequences are available on request. Eight micrograms of genomic DNA were digested overnight with suitable restriction enzymes (StuI or HindIII). Digested DNAs were electrophoresed on 1% agarose gel and blotted onto nylon filters. After hybridization with the radiolabeled probes, filters were exposed to X-Omat films (Kodak). Films were scanned for densitometry and analyzed using ImageJ software (http://rsb.info.nih.gov/ij).
Results.
We found genomic deletions of DCX in 27% (3 of 11) of women in whom DNA sequencing revealed no mutations. This finding increased from 52% to 65% (from 12 to 15 out of 23) the number of patients with either a mutation or a genomic deletion. We also confirmed a genomic DCX deletion in the boy with X-linked lissencephaly. Phenotypic characteristics and molecular findings of the patients harboring a genomic DCX deletion are briefly presented below.
Patient 1. Patient 1 was a 25-year-old woman with no family history of neurologic disorders. Motor and language development had been mildly delayed. Since the age of 8 years, partial and secondarily generalized seizures had appeared. Brain MRI showed diffuse SBH ( figure 1A) .
MLPA analysis revealed a deletion encompassing exons 3 to 5 of DCX ( figure 1B) . SQF-PCR confirmed the three exons' deletion (table). This patient was lost from followup, and Southern blot could not be performed because DNA was not available in the amount required.
Patient 2. Patient 2 was an 8-year-old girl with no relevant family history. From early infancy, language and motor development were mildly delayed. Infantile spasms occurred at the age of 6 months. Since the age of 5 years, she had developed intractable generalized seizures in the context of Lennox-Gastaut epilepsy. Brain MRI showed diffuse SBH with an AϾP gradient ( figure 1C) .
MLPA analysis revealed a deletion encompassing exon 6 of DCX ( figure 1D ). SQF-PCR (table) and Southern blot analysis ( figure 2, A and B) , complemented by densitometric quantification (figure 2, C and D), confirmed the single exonic deletion.
Patient 3. Patient 3 was a 15-year-old girl with no relevant family history. Motor and language development had been mildly delayed, but cognitive level was severely impaired. Since the age of 6 years, she had presented intractable atypical absence seizures and drop attack seizures in the context of Lennox-Gastaut syndrome. Brain MRI showed diffuse SBH with AϾP gradient ( figure 1E) .
MLPA analysis revealed a deletion encompassing exons 3 to 5 of DCX ( figure 1F ). SQF-PCR confirmed the three exons' deletion (table) . Because of the large extension of the deletion and the limited resolution of agarose gel, Southern blot did not show aberrant bands in a reliable fashion. However, we confirmed the deletions with a densitometric quantification of the Southern blot bands (figure 2, A, E, and F). Patient 4. Patient 4 was a 2-year-old boy with no family history of neurologic disorders. From early infancy, development was severely delayed. Since the age of 6 months, focal seizures and infantile spasms had appeared. Brain MRI showed severe diffuse lissencephaly with relatively small frontal lobes and rudimentary sulcal indentation limited to the mesial occipital lobes ( figure 3, A and B) .
In this patient, PCR amplification failed to obtain products for exons 3 and 4, suggesting a hemizygous deletion ( figure 3C ). These findings were confirmed using MLPA, which revealed a deletion of both exons ( figure 3D ). MLPA analysis performed in the boy's healthy mother was negative (data not shown).
Discussion. The number of patients with sporadic, diffuse, or anteriorly predominant SBH, harboring mutations in the DCX gene, was estimated to range from 53% 12 to 84% 13 in two previous studies in which gene sequencing was used. In our cohort of 23 patients with sporadic SBH, 52% (12 of 23) showed DCX mutations after sequencing, and subsequent MLPA assay identified genomic deletions of DCX in 27% (3 of 11) of the remaining women, raising to 65% the percentage of patients with sporadic SBH in whom a molecular involvement of DCX could be demonstrated. Therefore, deletions of DCX seem to be an underascertained cause of SBH, making MLPA a useful complement to DNA sequencing for mutation detection. SQF-PCR and Southern blot confirmed the reliability of MLPA in detecting deletion of even a single exon. For the remaining cases, either mutations in DCX that are not detectable with the present methods, cryptic chromosomal abnormalities involving the same gene, or involvement of additional SBH gene(s) are possible. The literature suggests that at least four additional genes may contribute to the cause of SBH in as many different malformation syndromes. Mosaic 10 or missense 8 mutations of LIS1 have been described in patients with posterior SBH. Posterior SBH has been reported in a girl with Baraitser-Winter syndrome. 18 Diffuse SBH was reported in a man with trisomy 9p 19 and in a girl with a syndrome featuring a simplified gyral pattern and syndactyly. 20 The deletions we identified encompassed exons 3 to 5 in two patients and exon 6 in one patient. All three deletions were predicted to cause depletion of the doublecortin protein, with consequent severe migration impairment. Indeed, brain MRI scan in these three patients showed thick, diffuse, or anteriorly predominant SBH with a simplified gyral pattern, accompanied by mental retardation and intractable epilepsy ( figure 1 , A, C, and E). These findings are in keeping with previous observations that nonsense and truncating DCX mutations, leading to protein loss of function, cause the more severe phenotypes. 13 In general, patients with thicker heterotopic bands and a simplified gyral pattern have more severe phenotypes, with worse developmental delay and significantly earlier seizure onset. 1 Severe impairment, in turn, causes reproductive disadvantage, increasing the likelihood for sporadic occurrence.
Large deletion involving exons 6 to 9 had previously been detected using PCR and Southern blot in a family in which a boy had XLIS and his sister had SBH. 13 A deletion involving exons 4 to 7 had also been identified by PCR in one boy with sporadic XLIS. 14 Both deletions had been identified first in hemizygous males with XLIS in whom PCR had failed to obtain an amplification product. Because heterozygous women with large deletions preserve a copy of one allele, they exhibit an apparently normal PCR amplification. Consequently, deletions in women might be underascertained if mutation analysis is performed with PCR-based methods (SSCP, DGGE, and DNA sequencing). Southern blot might uncover large deletions, although this method is complex and requires large DNA amounts. Conversely, MLPA represents a rapid and cost-effective complement to DNA sequencing of DCX, improving the overall mutation-detection rate.
Genetic counseling for individuals with diffuse or anteriorly predominant SBH must take into account the possibility of underascertainment of large deletions or duplications of the DCX gene. For this reason, if the results of a sequence analysis of DCX are negative, MLPA assay should be mandatory.
In the boy with XLIS who was included in this study, MLPA revealed a deletion of exons 3 and 4 of DCX and ruled out the same deletion in the leukocytes-derived DNA of the boy's mother, showing this method's usefulness for familial ascertainment of deletions that are revealed by standard mutation analysis in hemizygous boys. However, gonadal mosaicism for the deletion in the boy's mother still remains possible. MLPA might be useful for identification of somatic mosaicism for deletions, particularly in boys, in whom mosaicism might preclude large deletions to be identified with PCR-based methods, leading to apparently negative results. Molecular screening with MLPA might also be used to rule out somatic mosaicism in parents of seemingly sporadic patients with SBH and DCX deletions. However, further studies are necessary to estimate the variability and sensitivity of the MLPA method in the detection of somatic mosaics before this method can be used for such purposes.
